DLL3 Is Expressed in GEP-Neuroendocrine Neoplasms with Loss of RB1 and Has Prognostic Significance Abstract #3016

Introduction: The negative notch regulator DLL3 has gained increasing attention in tumors with neuroendocrine features, in particular SCLC, LCNEC and neuroendocrine prostate cancer, both as prognostic marker and candidate therapeutic target. No data are available on the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs).
Aim(s): The aim of the present study is to evaluate DLL3 expression in different GEP-NENs tissues and assess the correlation with disease stage, clinical features and RB1 loss.
Materials and methods: DLL3 and RB1 expression was retrospectively evaluated on FPPE samples from 43 patients with GEP-NENs. The immunostaining was scored positive if ≥1% of the tumor cells showed cytoplasmic/membranous (DLL3) or nuclear (RB1) localization.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: PhD Chiara Liverani

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1102 First-Line Chemotherapy in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC): A Retrospective Analysis
Introduction: Gastroenteropancreatic neuroendocrine neoplasia (GEP-NENs) are divided on the basis of Ki67 status into G1-G2 neuroendocrine tumors (NETs) (Ki67 <20%) and neuroendocrine carcinoma (NECs) (Ki67 >20% ). NEC patients generally have a poor prognosis and the first choice treatment is chemotherapy.A cisplatin/etoposide combination is often used as NECs are considered clinically similar to small cell lung cancer (SCLC), but no literature data is available. There is some evidence to suggest that carboplatin may also be effective in metastatic SCLC.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Alberto Bongiovanni
Keywords: GEP-NEC, chemotherapy
#1893 Peripheral Blood Biomarkers of Systemic Inflammation May Be Prognostic in Metastatic Gastroenteropancreatic Neuroendocrine Tumour (GEPNET) Patients Following 177Lu-DOTATATE (LuTate)
Introduction: LuTate is a treatment for well-differentiated NETs with adequate somatostatin receptor expression. Prognostic biomarkers in this population are lacking. Neutrophil-to-lymphocyte ratio (NLR) is prognostic in the majority of solid tumours but is reported to have less value in indolent well-differentiated NETs.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Biomarkers
Presenting Author: Dr Aimee Hayes
#3043 Angiogenetic Markers as Prognostic Predictors in Neuroendocrine Neoplasms
Introduction: Neoangiogenesis is crucial for NEN development and metastatization.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Giulia Puliani
Authors: Puliani G, Feola T, Sesti F, Sciarra F, ...
Keywords: biomarkers, prognosis
#583 Olfactory Receptor 51E1 is a Potential Novel Tissue Biomarker for the Diagnosis and Prognosis of Small Intestine Neuroendocrine Tumors
Introduction: Small intestine neuroendocrine tumor (SI-NET) patients get late diagnosis. We reported olfactory receptor 51E1 (OR51E1) as a SI-NET-mRNA marker.
Conference:
Category: Basic
Presenting Author: Mr TAO CUI
#1434 CA19-9 As a Prognostic Biomarker in Pancreatic Neuroendocrine Tumors
Introduction: Carbohydrate antigen19-9 (CA19-9) is generally not considered as a biomarker in pancreatic neuroendocrine tumors (pNETs) since most pNETs present with normal range of CA19-9.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Biomarkers
Presenting Author: Dr Kaizhou Jin
Authors: Luo G, Guo M, Liu Z, Liu C, ...